Findings
Digital biomarkers should align with the FDA-NIH definition of biomarkers as indicators of biological processes, avoiding conflation with COAs, which measure patient-reported or observed outcomes.
Digital biomarkers can consolidate data from multiple DHTs to derive context-rich health indicators, enhancing population baselines and patient-specific insights.
Applications include detecting atrial fibrillation via wearable sensors, monitoring tremors in Parkinson’s patients, and assessing gait in Huntington’s disease, each emphasizing specific biomarker categories (e.g., diagnostic or monitoring).
Inconsistent use of the term “digital biomarker” may impede communication between developers and regulators, complicating evidence requirements for medical product evaluation.
External factors, such as pollen counts for asthma or UV exposure for photosensitivity, can complement digital biomarkers, offering comprehensive health insights.

Recommendations
Standardize the term “digital biomarker” within the healthcare and regulatory communities to improve consistency in research and medical product evaluations.
Foster collaboration across the healthcare ecosystem to ensure DHTs are integrated effectively into clinical workflows and regulatory frameworks.
Explore opportunities to combine digital biomarkers with environmental data to enhance predictive and preventative healthcare applications.
Encourage ongoing validation of digital biomarkers through robust analytical and clinical studies to build confidence in their utility and regulatory acceptance.
Incorporate patient-centric design principles into DHTs to ensure usability and relevance across diverse patient populations.

Regulatory Considerations
Align digital biomarker definitions with FDA guidance to ensure clarity in regulatory submissions and evaluations.
Validate digital biomarkers with evidence that demonstrates analytical validity, clinical validity, and clinical utility for their intended use.
Include considerations for patient privacy and data security, especially when integrating external environmental data into digital biomarker systems.
Develop frameworks for evidence generation that address both individual patient and population-level health insights, enabling broad regulatory and clinical applications.
Establish clear pathways for incorporating digital biomarkers into the regulatory review process, including guidance on how to demonstrate reliability and relevance.